KONVANSİYONEL EKSTERNAL RADYOTERAPİ VE KONFORMAL RADYOTERAPİ TEKNİKLERİNİN HORMONOTERAPİ DURUMUNA GÖRE AKUT YAN ETKİLER AÇISINDAN KARŞILAŞTIRILMASI

Abstract

Amaç : Prostat kanserinin primer tedavisinde konvansiyonel eksternal radyoterapi (EBRT) ile konformal radyoterapi teknik (CRT)uygulamaların hormonoterapi (HT) durumuna göre akut yan etkiler açısından karşılaştırılması amaçlanmıştır. Gereç ve Yöntem : Mart 1997- Temmuz 2002 tarihleri arasında lokalize prostat kanseri tanısı konmuş ve primer radyoterapi uygulanmış 75 hastanın EBRT uygulanan 47 ve CRT uygulanan 28 hasta idi. Tüm hastalar için medyan yaş 72 (55-85), medyan radyoterapi dozu 70 Gray (Gy) (63-76 Gy) olarak tespit edilmiştir. Hastaların 23’u (%31) hormonoterapi almamış , 22’si (%29) eş zamanlı hormonoterapi almış ve 30’u (%40) neoadjuvan hormonoterapi almıştı. Hastaların en az 3 aylık takibi mevcut olup, görülen akut yan etkiler EORTC/RTOG (European Organisation for Research and Treatment of Cancer / Radiation Therapy Oncology Group) skalası kullanılarak değerlendirilmiştir 1 . Bulgular: Grade I ve II akut üriner yan etkiler; konvansiyonel radyoterapi grubunda %30 ve %23 iken, konformal radyoterapi grubunda %61 ve %18 oranında gözlenmiştir (p=0.025). Grade II üriner yan etkiler; HT almayanda ve neoadjuvan hormonoterapi alanlarda %13 eş zamanlı hormonoterapi alan hastalarda %41 oranında saptanmıştır (p=0.02). Grade II rektal yan etkiler; konvansiyonel radyoterapi grubunda %30, konformal radyoterapi grubunda %7 oranında tespit edilmiştir (p=0.022). Sonuç : Konformal radyoterapi uygulaması ile grade II akut rektal ve üriner yan etkilerin azaldığı tespit edilmiştir. Eşzamanlı hormonoterapi kullanımı ile grade II akut üriner yan etki neoadjuvan kullanıma göre daha sık gözlenmiştir.

Anahtar Kelimeler: Akut yan etkiler, Konvansiyonel, Konformal radyoterapi, Prostat kanseri

Keywords

• -

References

1. Cox JD, Stetz J, Pajak TF. Toxicity Criteria of the
2. Radiation Therapy Oncology Group (RTOG) and
3. the European Organization for Research and
4. Treatment of Cancer (EORTC). Int J Radiat Oncol
5. Biol Phys 1995; 31:1341-1346.
6. Zelefsky MJ, Leibel SA, Fuks Z. Conventional
7. external beam radiation therapy for prostate cancer:
8. Where do we go from here? Int J Radiat Oncol Biol

9. Phys 1993; 26:365-367.
10. Gallagher MJ, Brereton HD, Rostock RA, et al. A
11. prospective study of treatment techniques to
12. minimize the volume of pelvic small bowel with
13. reduction of acute and late effects associated with
14. pelvic irradiation. Int J Radiat Oncol Biol Phys
15. ; 12:1565-1573.
16. Leibel SA, Zelefsky MJ, Kutcher GJ, et al. The
17. biological basis and clinical application of threedimensional
18. conformal external beam radiation
19. therapy in carcinoma of the prostate. Semin Oncol
20. ; 21:580.
21. Sandler HM, Perez-Tamayo C, Ten Haken RK, et
22. al. Dose escalation for stage C (T3) prostate cancer:
23. Minimal rectal toxicity observed using conformal
24. therapy. Radiother Oncol 1992; 23:53.
25. Sandler HM, McLaughlin PW, Ten Haken RK,
26. Addision H, Forman J, Lichter A. Three
27. dimensional conformal radiotherapy for the
28. treatment of prostate cancer: low risk of chronic
29. rectal morbidity observed in a large series of
30. patients. Int J Radiat Oncol Biol Phys 1995;
31. :797-801.
32. Dale E, Olsen DR, Foss SD. Normal tissue
33. complication probabilities correlated with late
34. effects in the rectum after prostate conformal
35. radiotherapy. Int J Radiat Oncol Biol Phys 1999;
36. :385-391.
37. Hanks GE, Schultheiss TE, Hunt MA, Epstein BE.
38. Factors influencing incidence of grade 2 morbidity
39. in conformal and standard radiation treatment of
40. prostate cancer. Int J Radiat Oncol Biol Phys 1995;
41. :25-29.
42. Soffen EM, Hanks GE, Hunt MA, Epsteın BE.
43. Conformal static field radiation therapy of early
44. prostate cancer versus non-conformal techniques: A
45. reduction in acute morbidity. Int J Radiat Oncol
46. Biol Phys 1992; 24:485-488.
47. Koper PC, Stroom JC, Van Putten WL, et al. Acute
48. morbidity reduction using 3DCRT for prostate
49. carcinoma: A randomized study. Int J Radiat Oncol
50. Biol Phys 1999; 43:727-734.
51. Pollack A, Zagars GK, Smith LG, et al. Preliminary
52. results of a randomized radiotherapy doseescalation
53. study comparing 70 Gy with 78 Gy for
54. prostate cancer. J Clin Oncol 2000; 18:3904-3911.
55. Storey MR, Pollack A, Zagars G, Smith L, Antolak
56. J, Rosen I. Complications from radiotherapy dose
57. escalation in prostate cancer: Preliminary results of
58. a randomized trial. Int J Radiat Oncol Biol Phys
59. ; 48:635-642.
60. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose
61. escalation with three-dimensional conformal
62. radiation therapy affects the outcome in prostate
63. cancer. Int J Radiat Oncol Biol Phys 1998; 41:491-
64. -
65. Storey MR, Pollack A, Zagars G, Smith L, Antolak
66. J, Rosen I. Complications from radiotherapy dose
67. escalation in prostate cancer: Preliminary results of
68. a randomized trial. Int J Radiat Oncol Biol Phys
69. ; 48:635-642.
70. Fleming I, Cooper J, Henson D, et al. Prostate .In:
71. AJCC cancer staging manual. Philadelphia, New
72. York: Lippincott-Raven; 1997:219-224.
73. Tait DM, Nahum AE, Meyer LC, et al. Acute
74. toxicity in pelvic radiotherapy; a randomised trial
75. of conformal versus conventional treatment.
76. Radiother Oncol 1997; 42:121-36.
77. Pollack A, Zagars GK, Starkschall G, et al.
78. Conventional versus conformal radiotherapy for
79. prostate cancer: prelimary results of dosimetry and
80. acute toxicity. Int J Radiat Oncol Biol Phys 1996;
81. :555-564.
82. Vijayakumar S, Awan A, Karrison T, et al. Acute
83. toxicity during external beam radiotherapy for
84. localized prostate cancer: comparison of different
85. techniques. Int J Radiat Oncol Biol Phys 1993;
86. :359-371.
87. Nuyttens JJ, Milito S, Rust PF, Turrisi AT. Dosevolume
88. relationship for acute side effects during
89. high dose conformal radiotherapy for prostate
90. cancer. Radiother Oncol 2002; 64:209-214.
91. Odrazka K, Vanasek J, Vaculikova M,, et al.
92. Conformal radiotherapy for prostate cancer-longer
93. duration of acute genitourinary toxicity in patients
94. with prior history of invasive urological procedure.
95. Acta Oncol 2001; 40:7810-7815.
96. Herold DM, Hanlon AL, Hanks GE. Diabetes
97. Mellitus: A predictor for late radiation morbidity.
98. Int J Radiat Oncol Biol Phys 1999; 43:475-479.
99. Lim Joon D, Hasegawa M,Wu CS, et al. Supraadditive
100. apoptotic response in predominantly
101. quiescent prostate tumors when treated with
102. androjen-ablation and radiotherapy. Int J Radiat
103. Oncol Biol Phys 1996; 36:191.
104. Forman JD, Kumar R, Haas G, Montie J, Porter
105. AT, Mesina CF. Neoadjuvant hormonal downsizing
106. of localized carcinoma of prostate: effect on the
107. volume of normal tissue irradiation. CA Invest
108. ; 13:132-133
109. -
110. Marmara Medical Journal 2004;17(2);58-64
111. İlknur Çetin, et.al.
112. A comparison of Conventıonal External Radıotherapy Technique and Conformal Radiotherapy Technique in Terms of
113. Acute Toxıcity With Regard to Hormonal Treatment
114. Lawton CA, Winter K, Murray K, et al. Updated
115. results of the phase III radiation therapy oncology
116. group (RTOG) trial 85-31 evaluating the potential
117. benefit of androgen suppression following standard
118. radiation therapy for unfavorable prognosis
119. carcinoma of the prostate. Int J Radiat Oncol Biol
120. Phys 2001; 49;937-946.
121. Pilepich MV, Winter K, John MJ, et al. Phase III
122. radiation therapy oncology group (RTOG) trial 86-
123. of androgen deprivation adjuvant to definitive
124. radiotherapy in locally advanced carcinoma of the
125. prostate. Int J Radiat Oncol Biol Phys 2001;
126. :1243-1252.
127. Zurlo A, Collete L, van Tienhoven G, Blank L, et
128. al, EORTC Radiotherapy and Genito-Urinary Tract
129. Cancer Group. Acute toxicity of conventional
130. radiation therapy for high-risk prostate cancer in
131. EORTC trial 22863. Eur Urol 2002; 42:125-132
132. Sanguineti G, Franzone P, Marcenaro M, Paoli G,
133. Orsatti M, Vitale V. Androgen deprivation impacts
134. late rectal toxicity after conformal radiotherapy.
135. Abstr 1328, 338a. ASCO Meeting 2000; 20-23.